DrugPatentWatch Database Preview
Drugs in Development Information for Anlotinib
What is the development status for investigational drug Anlotinib?
Anlotinib is an investigational drug.
There have been 111 clinical trials for Anlotinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2019.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., and Sun Yat-sen University.
There are seven US patents protecting this investigational drug and fifty-five international patents.
Summary for Anlotinib
| US Patents | 7 |
| International Patents | 55 |
| US Patent Applications | 10 |
| WIPO Patent Applications | 12 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2019-01-01) |
| Vendors | 17 |
Recent Clinical Trials for Anlotinib
| Title | Sponsor | Phase |
|---|---|---|
| Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma | Affiliated Hospital of Guilin University | Phase 2 |
| Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma | Cancer Hospital of Guangxi Medical University | Phase 2 |
| Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma | First Affiliated Hospital of Guangxi Medical University | Phase 2 |
Clinical Trial Summary for Anlotinib
Top disease conditions for Anlotinib
Top clinical trial sponsors for Anlotinib
US Patents for Anlotinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Anlotinib | Start Trial | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)meth- yl)cyclopropanamine, its crystalline form and its salts | Advenchen Pharmaceuticals, LLC (Moorpark, CA) | Start Trial |
| Anlotinib | Start Trial | Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same | Start Trial | |
| Anlotinib | Start Trial | Method for treating tumour, pharmaceutical composition and medicinal kit | Start Trial | |
| Anlotinib | Start Trial | Quinoline derivative against non-small cell lung cancer | Start Trial | |
| Anlotinib | Start Trial | Spiro substituted compounds as angiogenesis inhibitors | Start Trial | |
| Anlotinib | Start Trial | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)meth- yl)cyclopropanamine, its crystalline form and its salts | Advenchen Pharmaceuticals, LLC (Moorpark, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Anlotinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Anlotinib | Australia | 2016257816 | 2035-05-04 | Start Trial |
| Anlotinib | Brazil | 112017023639 | 2035-05-04 | Start Trial |
| Anlotinib | Canada | 2984444 | 2035-05-04 | Start Trial |
| Anlotinib | China | 107771078 | 2035-05-04 | Start Trial |
| Anlotinib | China | 110172057 | 2035-05-04 | Start Trial |
| Anlotinib | Eurasian Patent Organization | 201792355 | 2035-05-04 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
